Clinical Trials on Adverse Drug Reaction in India

Total 60 results

Jung-min Ahn
CardioVascular Research Foundation, Korea

Active, not recruiting

Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery (ASSURE-DES)

Antiplatelet Drugs

Korea, Republic of, India, Turkey
Bayer

Recruiting

A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)

Chronic Heart Failure With Reduced Ejection Fraction | Worsening Heart Failure

India
LivaNova

Active, not recruiting

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System. (CORE-VNS)

Epilepsy | Seizures | Drug Resistant Epilepsy

Australia, Italy, United States, Israel, United Kingdom, Canada, Brazil, Japan, Belgium, India, Austria, China, Netherlands, Poland, Portugal, Saudi Arabia
Novartis Pharmaceuticals

Completed

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients (PARALLAX)

Heart Failure With Preserved Ejection Fraction

Colombia, Romania, United States, Austria, Belgium, Estonia, Turkey, Germany, Netherlands, Italy, Spain, Thailand, Argentina, France, Bulgaria, Hungary, Israel, Peru, Lithuania, Guatemala, India, Russian Federation, Denmark, Mexico, Slo... and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF)

Heart Failure With Preserved Ejection Fraction

China, Germany, United States, Colombia, South Africa, Italy, Austria, Belgium, Croatia, Romania, Taiwan, Japan, Netherlands, Denmark, France, Israel, Spain, Switzerland, Korea, Republic of, Argentina, Canada, United Kingdom, Bulgaria, Gree... and more
Novartis Pharmaceuticals

Completed

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Chronic Heart Failure With Reduced Ejection Fraction

India, Romania, Belgium, Czechia, Estonia, Hungary, Russian Federation, Taiwan, United Kingdom, Spain, Israel, Thailand, Canada, Korea, Republic of, United States, Bulgaria, Denmark, Netherlands, Philippines, Lithuania, Germany, T... and more
Novartis Pharmaceuticals

Terminated

This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure (PARADIGM-HF)

Heart Failure With Reduced Ejection Fraction

China, Germany, United States, Colombia, Korea, Republic of, Romania, South Africa, Canada, Belgium, Estonia, Hungary, Italy, Russian Federation, Taiwan, Turkey, United Kingdom, Spain, France, Netherlands, Hong Kong, Bulgaria, Israel and more
AstraZeneca

Completed

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF)

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

United States, Canada, Denmark, United Kingdom, Czechia, Vietnam, Germany, Brazil, India, China, Japan, Taiwan, Netherlands, Bulgaria, Slovakia, Hungary, Poland, Russian Federation, Argentina, Sweden
Eli Lilly and Company

Active, not recruiting

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial (SUMMIT)

Obesity | Heart Failure With Preserved Ejection Fraction (HFpEF)

China, United States, Taiwan, Mexico, Brazil, Puerto Rico, Argentina, Israel, India, Russian Federation
Novo Nordisk A/S

Completed

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes (STEP HFpEF DM)

Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2

United States, Spain, Hungary, United Kingdom, India, Netherlands, Germany, Japan, Canada, Czechia, Argentina, Austria, Israel, Italy, Poland, Sweden

Clinical Trials on Adverse Drug Reaction in India

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations